Related Experiment Video

Updated: Jun 14, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation:

Young-Kwang Yoon1, Hwang-Phill Kim, Sae-Won Han

  • 1Cancer Research Institute, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 110-744, Korea.

Molecular Carcinogenesis
|April 2, 2010
PubMed

Insights

Combinatorial therapy targeting MEK and JAK2, or MEK and EGFR, shows promise for non-small cell lung cancer (NSCLC) with KRAS mutations, depending on PTEN status.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • KRAS mutations are common in non-small cell lung cancer (NSCLC), activating the MEK/ERK pathway.
  • NSCLC often exhibits co-mutations in cancer-related genes, necessitating combination therapies.
  • MEK inhibitors are a potential therapeutic strategy, but responses vary based on genetic background.

Purpose of the Study:

  • To investigate MEK dependence and response to MEK inhibition in NSCLC cells with KRAS mutations.
  • To explore combinatorial therapeutic strategies for NSCLC harboring KRAS mutations, with or without PTEN co-mutation.
  • To identify biomarkers predicting response to MEK-targeted therapies in NSCLC.

Main Methods:

  • Characterization of MEK dependence in four NSCLC cell lines with different mutation profiles (KRAS only vs. KRAS/PTEN co-mutation).
  • Assessment of MEK inhibitor sensitivity and response to combination therapies (EGFR/MEK, JAK2/MEK).
  • Analysis of signal transducer and activator of transcription 3 (STAT3) activation in response to MEK inhibition.

Main Results:

  • NSCLC cells with KRAS mutation alone showed variable sensitivity to MEK inhibition.
  • Combination of EGFR and MEK inhibitors was effective in KRAS mutant NSCLC cells without PTEN co-mutation.
  • In KRAS/PTEN co-mutant NSCLC cells, MEK inhibition led to STAT3 activation; combined MEK and JAK2 inhibition synergistically suppressed growth and induced apoptosis.

Conclusions:

  • PTEN status is a critical determinant of response to MEK inhibition in KRAS-mutant NSCLC.
  • STAT3 activation is a key mechanism of resistance to MEK inhibition in KRAS/PTEN co-mutant NSCLC.
  • Combination therapy with MEK/EGFR inhibitors or MEK/JAK2 inhibitors, guided by PTEN status, offers a promising strategy for NSCLC treatment.

More Related Videos

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...